Skip to main content
    V

    Voyager Therapeutics Inc (VYGR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.63
    -0.10 (-5.78%)

    Market Cap: $107.66M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Voyager Therapeutics Inc (VYGR) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Voyager Therapeutics (VYGR) trades at 4.0x sales and 0.7x book value. Its P/S of 4.0x is above its 5-year median of 3.8x. Its forward P/E is 8.4x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E8.4x
    Price to sales4.0x
    Price to book0.7x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 29.8% below 5.7x and its P/B is 66.7% below 2.1x.

    MultipleCurrent5-year median10-year median
    P/S4.0x3.8x5.7x
    P/B0.7x1.4x2.1x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 1.4x in 2023 to 45.8x in 2017.

    Year endPriceP/EP/SP/B
    2025$3.93N/A5.7x1.2x
    2024$5.67N/A4.1x1.1x
    2023$8.442.7x1.4x1.6x
    2022$6.10N/A5.7x4.0x
    2021$2.71N/A2.7x1.1x
    2020$7.157.5x1.6x1.7x
    2019$13.95N/A4.9x5.2x
    2018$9.40N/A39.6x6.5x
    2017$16.60N/A45.8x3.6x
    2016$12.74N/A22.6x2.4x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About VYGR

    What is VYGR's forward P/E ratio?

    Voyager Therapeutics has a forward P/E ratio of 8.4x.

    Is VYGR stock overvalued?

    GNG's valuation label for VYGR is Undervalued.

    What is VYGR's price to sales ratio?

    Voyager Therapeutics has a price to sales ratio of 4.0x.